Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.35 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.35 |
| ▸ | IL2 | P60568 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.32 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27836284 | 0.88 | LTA4H (0.41) | LTA4HNPC1RAB9AHPGDSCHRNA7 | |
| SCHEMBL27003446 | 0.84 | LTA4H (0.40) | LTA4HNPC1RAB9AHPGDSCHRNA7 | |
| SCHEMBL6491170 | 0.81 | LTA4H (0.40) | LTA4HRAB9AHPGDSCHRNA7CHRNA10 | |
| SCHEMBL6638790 | 0.79 | LTA4H (0.41) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL374357 | 0.76 | ADRA1A (0.32) | NPC1RAB9ABRD4GUCY1B2GUCY1A2 | |
| SCHEMBL27836285 | 0.76 | LTA4H (0.38) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL377220 | 0.76 | IL2 (0.46) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL8229045 | 0.76 | LTA4H (0.42) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL1127714 | 0.76 | LTA4H (0.42) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL11508291 | 0.75 | IDO1 (0.34) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408756-B1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2408756-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408760-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7977362-B2 | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| WO-2010108067-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BACE1, BACE2, APP | LTA4H 838/4885NPC1 533/4885RAB9A 1484/4885 |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | APP, PSEN1, PSEN2 | LTA4H 1538/4885NPC1 1414/4885RAB9A 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.